BioSpace News Archive

Business

Doug Drysdale and Dr. Shaheen Lakhan Join SpineThera Board

SpineThera, Inc. announced that biopharma executive Doug Drysdale and physician-scientist Dr. Shaheen Lakhan have joined SpineThera’s board of directors to support the further clinical development of SX600 and expansion of SpineThera’s product development pipeline.

May 16, 2022
·
5 min read
Business

Eliem Therapeutics Reports First Quarter 2022 Financial and Business Highlights

Eliem Therapeutics, Inc. provided a business update and reported financial results for the quarter ended March 31, 2022.

May 16, 2022
·
10 min read
Deals

Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties

Chimerix announces it has entered into a definitive agreement with Emergent BioSolutions Inc. to acquire its exclusive worldwide rights to brincidofovir, including TEMBEXA®.

May 16, 2022
·
4 min read
Deals

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc., to acquire Chimerix’s exclusive worldwide rights to TEMBEXA®, the first antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox.

May 16, 2022
·
7 min read
Business

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

Cullinan Oncology, Inc. reported on recent and upcoming business highlights and announced its financial results for the first quarter ended March 31, 2022.

May 16, 2022
·
11 min read
Pharm Country

RVL Pharmaceuticals plc to Present at Upcoming Conferences - May 16, 2022

RVL Pharmaceuticals plc, a specialty pharmaceutical company, announced that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:

May 16, 2022
·
1 min read
Pharm Country

NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis

NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis.

May 16, 2022
·
9 min read
Business

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported financial results for the quarter ended March 31, 2022 and provided a business update.

May 16, 2022
·
13 min read
Business

Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results

Protalix BioTherapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a business update on recent corporate and clinical developments.

May 16, 2022
·
13 min read
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference

ObsEva SA announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022.

May 16, 2022
·
1 min read